Dr Manjiri Bakre is the founder and CEO of OncoStem Diagnostics, a Bengaluru company behind CanAssist Breast. It is an AI-based test that helps doctors judge whether a woman with early-stage breast cancer really needs chemotherapy. After more than a decade in cancer research in the US, Singapore and India, she founded OncoStem in 2011 to build tests designed for Indian patients.
Who is Manjiri Bakre, and what is OncoStem? Manjiri Bakre is a cancer biologist with a PhD from IISc. OncoStem Diagnostics, which she founded, makes CanAssist Breast, a prognostic test that combines tumour biology markers with machine learning to predict the risk of breast cancer coming back. According to the company, more than 12,000 patients have been tested, and about 70% were found to be low-risk and could potentially avoid chemotherapy.
Who is Manjiri Bakre? Background
Manjiri studied science at Ruia College in Mumbai, did her master’s in Baroda and earned a PhD at the Indian Institute of Science (IISc), Bengaluru. Her research career included:
- Mount Sinai School of Medicine, New York (1998–2000)
- Moores Cancer Center, UC San Diego (2000–2003)
- Genome Institute of Singapore (2003–2007)
- Avesthagen, Bengaluru (2007–2009)
- Philips Research, Bengaluru (2009–2011)
Across these roles she saw a gap. The best cancer tests were developed for Western patients, were very expensive and were rarely validated on Indian tumours. She explained her goal simply:
“I founded OncoStem Diagnostics, to develop new and innovative tests for cancer patients to plan their treatment.”
The business idea: stop over-treating breast cancer
Many women with early-stage, hormone-receptor-positive breast cancer are given chemotherapy “just in case”, even though a large share would do just as well without it. Chemotherapy is expensive, can be toxic and disrupts lives. Imported genomic tests that help with this decision can cost lakhs of rupees, which puts them out of reach for most Indian patients.
OncoStem’s CanAssist Breast works differently:
- It tests a set of tumour biomarkers using immunohistochemistry on the existing biopsy sample.
- A machine-learning model combines those results with clinical factors to classify recurrence risk as low or high.
- Doctors use the result to decide whether chemotherapy is likely to help.
It was developed and validated on Indian and Asian patient cohorts and priced well below imported alternatives.
Challenges
- Clinical validation: years of studies were needed to win oncologists’ confidence.
- Trust in Indian innovation: as Manjiri told YourStory, “There’s still not enough trust for Made in India products.”
- Long R&D timelines: diagnostics companies spend years before earning revenue.
- Doctor and patient education: changing an established treatment habit takes time.
Growth journey: key milestones
| Year | Milestone |
|---|---|
| 2011 | OncoStem Diagnostics founded in Bengaluru |
| 2016 | CanAssist Breast introduced to the market |
| 2017 | Raised US$6 million in a round led by Sequoia Capital (YourStory) |
| Today | 12,000+ patients tested, according to the company; the test is used in India and other markets |
Leadership lessons from Manjiri Bakre
- Build for your own population. A test validated on Indian patients answers questions imported tests can’t.
- Affordability is innovation. Lowering the cost of a decision can change care for millions.
- Science first, then scale. Rigorous validation is the foundation of a diagnostics business.
- Global experience, local mission. Years abroad prepared her to build in India.
- Keep the patient at the centre. Avoiding unnecessary chemotherapy protects quality of life.
Read about another founder fighting breast cancer with AI in our profile of Geetha Manjunath and NIRAMAI, and explore more women entrepreneurs in India.
What’s next for OncoStem
OncoStem aims to make CanAssist Breast a standard part of early breast cancer care in India and other markets. It is also building more AI-driven prognostic tests to personalise cancer treatment beyond one-size-fits-all protocols.
FAQs
Who founded OncoStem Diagnostics?
Dr Manjiri Bakre founded OncoStem Diagnostics in Bengaluru in 2011 and serves as its CEO.
What is CanAssist Breast?
CanAssist Breast is an AI-based prognostic test for early-stage breast cancer. It predicts recurrence risk to help doctors decide whether chemotherapy is needed.
How is CanAssist Breast different from imported tests?
It was developed and validated on Indian and Asian patients and costs much less than imported genomic tests.
How many patients have used CanAssist Breast?
The company reports more than 12,000 patients tested. About 70% were classified as low-risk.
Who funded OncoStem?
OncoStem raised US$6 million in 2017 in a round led by Sequoia Capital, as reported by YourStory.
This article is for general information and is not medical advice. Patients should discuss testing and treatment with their oncologist.
Conclusion
The Manjiri Bakre and OncoStem story shows how deep scientific training and a focus on Indian patients can produce affordable, world-class diagnostics, and spare thousands of women unnecessary chemotherapy.
Sources
- The Global Indian: Manjiri Bakre and CanAssist Breast
- YourStory: OncoStem raises $6 million led by Sequoia Capital
- YourStory: Dr Manjiri Bakre on CanAssist Breast
- YourStory HerStory: How CanAssist Breast uses AI (2026)
Last updated: November 2026
